Aneesh Karatt Vellatt | Chief Scientific Officer
Maxion Therapeutics
Dr. Aneesh Karatt-Vellatt is Chief Scientific officer and co-founder at Maxion Therapeutics Ltd (Cambridge UK), a company focused on developing antibody treatments for diseases driven by ion channels and GPCRs. Dr Karatt Vellatt was also co-founder of IONTAS Ltd and holds a PhD in Biochemistry from the University of Cambridge.
Appearances:
Festival of Biologics Day 2 @ 17:50
Conquering The Last Frontier: Developing Ion Channel Modulating Antibodies
Ion channels are an important target class implicated in several untreated or poorly treated diseases. Despite the unmet need and the potential of monoclonal antibodies (mAbs) in this domain, no mAbs targeting ion channels have achieved clinical approval or are in clinical development. Maxion has shown that small cysteine-rich miniproteins (knottins) with ion-channel modulating activity can be inserted into antibody CDRs to create a novel mAb format called KnotBodies. KnotBodies maintain the ion channel activity of knottins while benefitting from the optimal drug-like properties of antibodies. This presentation will illustrate the discovery and optimisation of KnotBody inhibitors to therapeutically relevant ion channel targets.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events